AFP and hepatocellular carcinoma: The largest randomised control trial (RCT) for surveillance of HCC, using AFP and US, analysed 18,816 patients with HBV infection or a history of chronic hepatitis from China and showed a clear benefit of reduction in stage at diagnosis and mortality rates for the patients undergoing surveillance [3].